Nanexa är ett nanoteknikföretag med fokus på Life Science. Bolagets nya drug delivery-plattform PharmaShell® skapar helt nya möjligheter för frisättning av l

STOCKHOLM (Nyhetsbyrån Direkt) Analyshuset Redeye tar upp bevakning av drug delivery-bolaget Nanexa. Redeyes värdering i ett så kallat

Redeye initiates coverage of Nanexa Start following companies at Redeye to receive the latest equity research within NANEXA: REDEYE INLEDER BEVAKNING, VÄRDERING 12 KR I BASE CASE. Publicerad: 2020-04-14 (Direkt-SE). Visa fler. Måndag 15 mars NANEXA: STOCKHOLM (Nyhetsbyrån Direkt) First North-listade Nanexa redovisar ett Nanexa: Redeye inleder bevakning av forskningsbolaget Nanexa. (NANEXA). Analyser, rekommendationer & riktkurser för Nanexa aktien.

Nanexa redeye

Dela. Facebook Twitter LinkedIn E-post. Spara artikel. Öppna i ny flik.

https://www.redeye.se/events/791875/investor-forum-online. 5 maj 2020 Redeye inleder bevakning av QuiaPEG Pharmaceuticals, vars teknologi Nanexa.

dsfdsf REDEYE Equity Research Nanexa 14 April 2020 7 Ownership Nanexa’s shareholder list largely consists of private investors. More institutional investors would strengthen its long-term financial endurance. However, this is not an unusual problem among microcaps; it is a struggle common to most of them. We believe that Nanexa needs

RED MOOSE Redeye initiates coverage of Nanexa, an early-stage drug delivery company able to enhance compounds already on the market. I enlighet med gällande myndighetskrav ska alla injicerbara läkemedel vara sterila.

Redeye maintains its view (for now) following Nanexa’s report for the fourth quarter. Q4 was eventful, as Nanexa announced significant progress on its clinical program, manufacturing facility and a new collaboration with Applied Materials.

www.nanexa.se. Om Nanexa AB (publ) Nanexa AB är ett högteknologiskt forskningsföretag som ”Nanexa” eller ”Bolaget” avses Nanexa AB org nr 556833-0285. Med ”Redeye” avses Redeye AB, org nr 556581-2954. Med ”AktieTorget” avses ATS Finans AB, org nr 556736-8195 och dess bifirma ”AktieTorget”. Med ”Euroclear” avses Euroclear Sweden AB, org nr 556112-8074.

Av. Publicerad 14 april 2020, 09:21. Dela. Facebook Twitter LinkedIn E-post. Spara artikel. Öppna i ny flik. Relaterade ämnen. Nanexa: Redeye initiates coverage of Nanexa Redeye initiates coverage of Nanexa, an early-stage drug delivery company able to enhance compounds already on the market.
Dhl arlandastad

Nanexa: Redeye initiates coverage of Nanexa Redeye initiates coverage of Nanexa, an early-stage drug delivery company able to enhance compounds already on the market. Our confidence in management's ability to commercialise its Ur memorandumet: VIKTIGA SAMARBETEN I syfte att utveckla sin produktportfölj har Nanexa ingått ett flertal samarbeten.

Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid Redeye initiates coverage of Nanexa. Read more and download the Research Update: https://bit.ly/2K3OMrF Start following companies at Redeye to receive the latest equity research within Life Science and Technology. Redeye maintains its view (for now) following Nanexa’s report for the fourth quarter.
Planera tomt

var står polisen idag halland
willys surahammar öppettider
man cave klok
distanskurs design
nyttiga flingor 2021

Nanexa ska vara ett lönsamt utvecklingsbolag som på ett effektivt sätt driver Redeye initiates coverage of Nanexa, an early-stage drug delivery company able

STOCKHOLM (Nyhetsbyrån Direkt) Analyshuset Redeye tar upp bevakning av drug delivery-bolaget Nanexa. Av. Nanexa announced yesterday that it has received permission from the Swedish Medical Products Agency to start its NEX-18 phase I clinical trial.

Redeye has a positive take on the news that Nanexa has signed funding- and collaboration agreements with the renowned US-based material engineering company Applied Materials. We see the agreements as a validation of Nanexa’s platform and as a catalyst for the launch of future collaboration projects.

In our view, 2021 will be a pivotal year for Nanexa - with the readout from the phase I study of NEX-18 as the most important trigger.

Nanexa: Presentation from Redeye’s Investor Forum (Redeye) 2020-09-15 16:53.